Takeda's Q3 FY '25 results reflect resilient fundamentals despite the ongoing impacts from VYVANSE generic erosion, with promising advancements in their late-stage pipeline expected to drive future growth.

• Revenue for the first nine months decreased 3.3% to over JPY 3.4 trillion, with core operating profit down 3.4% year-on-year, but showing improvement from H1.
• Growth and launch products contributed over 50% of total revenue, growing 6.7% at constant exchange rates, signaling a rebound in the latter half of the fiscal year.
• Significant product advancement: Regulatory filings for key assets oveporexton and rusfertide completed, with expected launches within the next 18 months, potentially transforming treatment standards in their respective markets.
• Strong cash flow reported at JPY 625.9 billion, indicating prudent financial management amidst product transitions.
• Pipeline expansion with potential from new strategic partnerships, enhancing long-term growth trajectories beyond generic erosion impacts.